BMS rivals pushed bidding on Inhibitex; Janssen opens lab for biotech startups; Array CEO resigns;

@FierceBiotech: Constellation inks $95M discovery deal, buyout option with Genentech on new epigenetic drug programs. News | Follow @FierceBiotech

@JohnCFierce: Say goodnight, gracie. Dimebon fails final Ph3, Pfizer dumps monster partnership. Release | Follow @JohnCFierce

@MarkHFierce: Researchers are challenging studies that linked hormone replacement therapy to cancer based on "flawed" data. More | Follow @MarkHFierce

@RyanMFierce: Verastem's IPO plan seems to me like a bet on people as much as promise of new cancer stem cell targets. Article | Follow @RyanMFierce

> Anyone trying to figure out the dynamics behind the recent eye-popping buyouts of hepatitis C drug developers should check out a report from Bloomberg late last week, which tracked down the interesting fact that Bristol-Myers Squibb raised its bid for Inhibitex twice in five days as it countered offers from an unnamed rival. BMS began its courtship of the biotech with a $550 million bid last October, ending at nearly 5 times that amount by the time the dust had settled. Story

> J&J's Janssen Research & Development has opened up a 30,000 square foot lab in San Diego designed to cater to startup biotechs in the area. Release

> Six months after cutting back its workforce, Array BioPharma announced that CEO Robert Conway has resigned, citing personal reasons for the departure. Release

> Valeant ($VRX) bumps its offer to buy ISTA Pharmaceuticals by at least 15%. Story

> Alnylam ($ALNY) has filed a suit against Tekmira claiming patent infringement of its RNA technology. Release

Pharma News

 @FiercePharma: Launch angst among investors, analysts say: 'People are all freaked out'--Reuters. Article | Follow @FiercePharma

> Bit by bit, Lundbeck trims fat from production costs. Article

> Generics market to bulk up by $100B in 5 years. Story

Biotech Research News

> Sugar molecules betray precancerous cells in esophagus. More

> Hormone irisin eyed as possible weight loss drug ingredient. Item

> Vitamin D helps (more than) 3 (nearly) blind mice see. Article

> PARP inhibitors could aid larger ovarian cancer patient population. News

> Altering intestional bacteria with probiotics improved rats' heart health. Story

IT News

> Cannabis company launches Jane-Ome app. Item

> PerkinElmer CEO arranges marriage between informatics, lab service biz. More

> Entelos stages comeback bid with funding. Article

> AB Sciex, Indigo BioSystems join forces on mass spectrometry software. Story

> DecisionView updates clinical trial enrollment software. News

Manufacturing News

> Roche pilots direct shipments to Europe. News

> Abbott dodges excise tax at Indian plant. Story

> Daiichi sends Japanese execs to new Ranbaxy plant in India. More

> FDA: Novartis plant shows patterns of problems. Story

> USP has credibility as pedigree driver. Article

And Finally... A new "smart" pill has been developed that helps keep patients on track with their drug regimen. Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.